Pancreatic stem cell proliferator boosts beta, alpha cell populations.
TORRANCE, Calif., May 11, 2015--Celprogen Inc. has developed a synthetic molecule that is capable of stimulating growth and proliferation of pancreatic beta and alpha cell populations.
STEMC7007 can be administered by intravenous, intra-peritoneal and intramuscular injections, and oral doses.
The molecule activates adult pancreatic beta and alpha cell populations. STEMC7007 establishes normal beta cell function in diabetic cell populations by producing and secreting insulin and glucagon in invitro cell culture system.
STEMC7007 was developed by Celprogen using proprietary stem cell tissue culture technology. It works by restoring the human beta and alpha cell populations in the pancreas. The alpha cells of the pancreas are involved in glucagon production whereas the beta cells are involved in insulin production.
STEMC7007 works at the protein and gene expression levels to increase: insulin gene expression levels as well as this hormone secretion by the pancreas; glucagon gene expression levels as well as this hormone secretion by the pancreas; somatostatin gene expression as well as this hormone secretion by the pancreas; and glucose transporter gene expression and increase protein levels
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Cells & Cell Culture|
|Publication:||Stem Cell Business News|
|Date:||May 18, 2015|
|Previous Article:||Diabetic nephropathy trial results to be presented in June.|
|Next Article:||Adult stem cell packets for degenerative conditions.|